<DOC>
	<DOCNO>NCT02301156</DOCNO>
	<brief_summary>This study evaluate addition ublituximab , novel monoclonal antibody , ibrutinib compare ibrutinib alone previously treat Chronic Lymphocytic Leukemia ( CLL ) patient high-risk cytogenetic feature . Half participant receive ublituximab combination ibrutinib , half receive ibrutinib alone .</brief_summary>
	<brief_title>Ublituximab Combination With Ibrutinib Versus Ibrutinib Alone Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Previously treat Chronic Lymphocytic Leukemia ( CLL ) require treatment At least one highrisk cytogenetic feature define presence 17p deletion , 11q deletion and/or p53 mutation Eastern Cooperative Oncology Group ( ECOG ) score 0 2 Any major surgery , chemotherapy immunotherapy within last 21 day Evidence hepatitis B virus , hepatitis C virus know HIV infection Autologous hematologic stem cell transplant within 3 month study entry . Prior Allogeneic hematologic stem cell transplant exclude Transformation CLL aggressive NonHodgkin 's Lymphoma ( NHL ) ( Richter 's transformation ) Previous therapy ibrutinib , drug specifically inhibit Bruton 's tyrosine kinase ( BTK )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>